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Abstract 
Background: Mutations in the telomerase complex (TERT and TR) are associated with 
pulmonary fibrosis and frequent hematological manifestations. The aim of this study was to 
characterize the prognosis of lung transplantation in patients with TERT or TR mutations.  
Methods: Patients with documented TERT or TR mutations who received a lung transplantation 
in 2007-2013 in France were identified exhaustively through the lung transplantation network, 
one expert genetic laboratory, and the clinical research network on rare pulmonary diseases. 
Results: Nine patients (7 men) with TERT (n=6) or TR (n=3) mutations received a single (n=8) or a 
double (n=1) lung transplantation for pulmonary fibrosis. Median age was 50 years [range, 35-
61] at diagnosis and 52 years [37-62] at the time of lung transplantation. Seven patients had 
thrombocytopenia before lung transplantation. Six patients developed myelodysplasia and/or 
bone marrow failure after lung transplantation, directly contributing to death in 4 cases. Anemia 
and neutropenia were observed in 9 and 3 patients, respectively. The median survival after lung 
transplantation was 214 days [59-1709].  
Conclusion: Patients with mutations of the telomerase complex are at high risk of severe 
hematological complications after lung transplantation namely bone marrow failure. Specific 
recommendations should be developed for appropriate guidance regarding the hematological 
risk assessment before transplantation and the management of post-transplantation 
immunosuppressive regimen. 
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INTRODUCTION 
 
Idiopathic pulmonary fibrosis (IPF) is associated with a median survival time of about 3 years [1]. 
Lung transplantation has been shown to improve survival in selected patients [2]. The 
prevalence of IPF is estimated at 1/2500 to 1/7000, and 2% to 20% of IPF patients have at least 
one first-degree family member with a fibrotic lung disease [3-4]. Genetic studies in familial 
forms of IPF led to the discovery of mutations within TERT (encoding the telomerase reverse 
transcriptase) and TR (encoding the telomerase RNA component), which are both required for 
normal telomerase activity [5]. Heterozygous mutations within TERT or TR are detected in 15% 
to 20% of the cases of familial forms of pulmonary fibrosis (PF), whereas they are very rarely 
detected in sporadic IPF (<3%) [5-7]. In addition to PF, mutations in the telomerase complex are 
associated with mucocutaneous abnormalities such as dyskeratosis congenita (abnormal skin 
pigmentation, nail dystrophy, oral leukoplakia), and possibly severe complications including liver 
cirrhosis and bone marrow failure. As the phenotype may be heterogeneous and the same TERT 
mutations can be associated with different phenotypes of lung disease even in the same family 
[8], individual risk prediction is challenging.  
We recently evidenced a TERT mutation in a patient with PF, who developed bone marrow 
failure following lung transplantation, triggering the present study. The largest published 
experience only reports 8 patients with telomerase mutations and lung transplantation from 3 
different countries [9]. Therefore we reviewed the results of lung transplantation in all the 
patients with PF associated with TERT or TR mutations in France, in order to determine whether 
these patients were at risk of hematological complications. 
METHODS 
PATIENTS 
In this retrospective, observational, non-interventional study, all ten French lung transplant 
centers were contacted in order to identify patients with TERT or TR mutations referred for lung 
transplantation during the 2009-2013 period, as the laboratory of genetics began to perform 
these sequencing in 2009. In addition, cases were cross-identified through the only genetic 
laboratory in France that centrally assesses for telomerase mutations, and by the Groupe 
d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P), a 
collaborative group dedicated to research on rare (so-called “orphan”) pulmonary diseases.  
All the patients with PF with known mutations of TERT or TR who received a lung 
transplantation during the study period in France were included. The clinical charts of the 
patients were reviewed and data were collected on a standardized and anonymous collection 
form. Chest CT scans, biopsies and explants were systematically classified based on a 
multidisciplinary team discussion in each of the 4 expert centers involved in this study and 
classified according to the 2011 official ATS/ERS/JRS/ALAT statement for IPF [2, 10] and the 
revised classification of idiopathic interstitial pneumonia [11]. Haematogical manifestations 
including myelodysplastic syndromes were classified according to the 2008 WHO classification 
[12]. 
All patients or relatives gave signed consent for genetic analysis. The Institutional Review Board 
of the French learned society for respiratory medicine -Société de Pneumologie de Langue 
Française- approved this study (CEPRO 2012-016). 
Survival and characteristics at the time of lung transplantation were compared to a control 
group of patients with PF, extracted from the database of Agence de Biomedicine that collects 
data from all organ transplants in France, for the same period (2009-2013) and same centers. 
During the 2009-2013 period, 9 patients with known TERT or TR mutations included in this 
series, and 196 patients with non-familial PF and unknown mutational status received lung 
transplantation. Physicians in charge of lung transplantation in corresponding centres were 
queried for occurrence of myelodysplastic syndrome following transplant. 
TERT AND TR SEQUENCING  
Exons, intron-exon junctions and promoters of TERT and TR were sequenced by bi-directional 
sequencing (primers sequences available on request) and compared to the reference sequences 
for TERT : NM_198253.2 and TERC : NR_001566.1.  
TELOMERE LENGTH 
The telomere length was evaluated by terminal restriction fragment assay. DNA from blood cells 
was extracted, digested by the Hinf1 and Rsa1 nucleases (which do not digest telomere DNA 
sequences), submitted to a Southern blot using a specific telomere probe, and compared to 
those found in healthy age-matched controls [13]. 
STATISTICAL ANALYSIS 
Data for continuous variables are expressed as median (range) and were compared by the 
Mann-Whitney U test. Categorical variables were expressed as counts and proportions and 
compared by the Fisher’s exact test. Survival was studied and compared with a Kaplan-Meier 
analysis. Categorical variables are expressed as number and percentage and were compared by 
the Fisher’s exact test. All tests were two-sided, with p < 0.05 indicating statistical significance. 
All analyses used the Graph-Pad Prism 5 software (La Jolla, Ca, USA). 
RESULTS 
Clinical characteristics at the diagnosis of pulmonary fibrosis  
Nine patients with TERT or TR mutations received lung transplantation in France from January 
2009 to October 2013. The main clinical characteristics of the patients at diagnosis are shown in 
Table 1. Interstitial lung disease was diagnosed as IPF in 7 patients, pneumoconiosis in 1 patient, 
and chronic hypersensitivity pneumonitis in 1 patient. Six patients had some degree of exposure 
to inhaled contaminants (Table 1). Six patients presented with extra-pulmonary manifestations 
suggestive of telomere syndrome: 5 with hematological abnormalities, 1 with isolated 
unexplained liver enzymes elevation, and 3 with mucocutaneous abnormalities: nail dystrophy 
(n=2), hypopigmented macules (n=1), premature hair graying (n=1), and mucosal leukoplakia 
(n=1).  
Median age at PF diagnosis was 50 years [range, 35-61]. Patients had pulmonary symptoms for 
6 months [1-59] prior to the diagnosis of lung fibrosis. Dyspnea was the most frequent symptom 
(n=8), although one patient was asymptomatic at the time of diagnosis. Pulmonary function 
tests (PFT) results showed a reduced vital capacity (VC) (63% [40-88] of the predicted value) 
with reduced diffusion capacity for carbon monoxide (DLCO) (38% [16-77] of predicted).  
The CT scans were reviewed and classified as definite usual interstitial pneumonia (UIP) pattern 
in 5 cases, possible UIP pattern in 3 cases, and consistent with chronic hypersensitivity 
pneumonitis in 1 patient. A video-assisted surgical lung biopsy was performed before lung 
transplantation in 5 patients; 3 samples were classified as a definite UIP pattern, 1 as a probable 
UIP pattern and 1 as unclassifiable fibrosis. Lung explants were classified pathologically as UIP 
pattern in 2 cases, probable UIP pattern in 5 cases (absence of fibroblast foci), not UIP pattern in 
2 cases. The diagnosis was pneumoconiosis in one case; due to the presence of granuloma, the 
diagnosis of chronic hypersensitivity pneumonitis was suggested in one case. 
The median follow-up between the PF diagnosis and lung transplantation was 24.6 [4.5-72.2] 
months. Before transplantation, all patients received corticosteroids, 5 patients had received 
immunosuppressants (azathioprine, n=3; cyclophosphamide, n=2), and 2 patients received 
pirfenidone (Table 2). None of the treatment was associated with any objective pulmonary 
improvement assessed either by CT scan or an increase in VC or DLCO by 10% of the predicted 
value or greater. At the last visit before transplantation, VC and DLCO were 42% [75-22] and 
22% [15-33] of predicted, respectively.  
Genetic analysis 
Telomerase mutations were identified before (n=5), or after lung transplantation (n=4) (Table 
3), including post-mortem in two cases. Indication of TERT and TR sequencing were a familial 
history of lung fibrosis (n=4), hematological abnormalities (n=2), or both (n=3). Two patients 
presented with both personal hematological abnormalities and a familial history of lung fibrosis 
and thrombocytopenia. Telomere lengths measurement was near or below 5kb, and considered 
as abnormally short compared to age-matched controls in all 5 tested cases [13]. 
Hematological abnormalities before transplantation 
At the time of PF diagnosis and prior to any therapy, 4 patients had thrombocytopenia with a 
median platelet count of 59 G/L [50-66], and 1 patient had mild anemia (113 g/L) (Figure 1). 
During the pre-transplant period, 3 additional patients developed thrombocytopenia (53, 108 
and 135 G/L, respectively), including 1 patient who received corticosteroids and pirfenidone 
alone, and 2 patients who were treated with azathioprine. Proband #5 received azathioprine 
before lung transplantation and did not develop cytopenia. Six patients had macrocytosis (mean 
corpuscular volume, 101 fL [101-103]) before lung transplantation, at the time of the lung 
fibrosis diagnosis in two patients, and during follow-up in four additional patients. Three of 
them had received azathioprine, but macrocytosis persisted after azathioprine withdrawal. 
During follow-up, only 1 patient developed macrocytic non-regenerative anemia (117 g/L). 
Neither neutropenia, nor monocytosis greater than 1 G/L developed in any patients. Two 
patients received cyclophosphamide before lung transplantation, and did not have 
hematological complications. Bone marrow cytology was available in 4 patients before lung 
transplantation (Table 4) considered as normal in 1 patient, and consistent with the diagnosis of 
refractory cytopenia with unilineage dysplasia in the 3 others. Karyotype was normal in all 4 
tested cases. 
General evolution in the post transplantation period 
Eight patients received a single-lung transplantation and 1 patient received a double-lung 
transplantation. Five patients underwent high emergency lung transplantation. Table 2 shows 
the post-transplantation therapies received. None of them received alemtuzumab or anti-
thymocyte globulin. The median survival from the time of transplantation was 214 days (Figure 
2). At the end of follow-up, 3/9 patients were alive, 310, 747 and 1709 days after 
transplantation. The causes of deaths are indicated in Table 4. Two patients with persistent 
pancytopenia received multiple platelets and blood transfusions, granulocyte-colony stimulating 
factor (G-CSF) and erythropoietin injections. Hematopoietic stem cell transplantation was not 
considered and palliative care was started. Finally, death occurred and was attributed to 
refractory pancytopenia. Two patients died from sepsis, related to Staphylococcus haemolyticus 
and Enterobacter cloacae, respectively; neutrophil counts were within the normal range, 
whereas platelet counts were reduced at 25 G/L and 9 G/L. In those patients, deaths likely 
occurred because of the lung transplantation complications and myelodysplastic syndromes. 
One patient died from pulmonary embolism unrelated to myelodysplastic syndrome. The cause 
of death remained unknown for one patient. Two of the 3 living patients have myelodysplastic 
syndromes.  
Lung function tests were available after lung transplantation in 5 patients, all with single-lung 
transplantation. Forced expiratory volume in 1 second (FEV1) was 48% [38-64] and 40% [28-68] 
of the predicted values, 3 and 6 months after transplantation, respectively. The best FEV1 
available was 50% [38-74] of the predicted values. In the 3 patients alive, the last follow-up visit 
showed a FEV1 of 44%, 53%, and 59% of the predicted values, respectively. During follow-up, 
three patients developed acute transplant rejection requiring increased doses of 
corticosteroids. The diagnosis of rejection was made after clinical suspicion and not on 
systematic biopsies. One patient developed a second episode of acute rejection. The severity of 
acute rejection was classified with transbronchial biopsies as A1B0 for 2 patients, and clinically 
highly suspected for one patient but not confirmed by histology because of thrombocytopenia. 
Based on PFT, none of them developed bronchiolitis obliterans syndrome.  
Comparison with a control group  
Patients from the control group with pulmonary fibrosis and unknown mutational status 
(N=196) were more frequently women (25%, P=0.03). Their median age was 55.4+/-3.0 years 
(P=0.12 vs mutated patients). The diagnosis of myelodysplastic syndrome was given in 2 
patients from the control group.  
The median survival of the control group was 1301 days and was not statistically different from 
the mutated group (p=0.85). Lung transplantation was less frequently a high emergency 
procedure in controls than in mutated patients (25% vs 55%, P=0.04). In the control group, high 
emergency procedure was associated with poorer survival (167 days for high emergency 
procedure vs 1437 days without high emergency procedure, P=0.004). After excluding patients 
transplanted with high emergency procedures, survival was not different between the control 
and mutated groups.  
Post-transplantation infections and hematological abnormalities  
Due to the frequent use of extracorporeal circulation in the perioperative period, the nadir of 
thrombocytopenia was defined starting at day 7 post-transplantation. Thrombocytopenia 
worsened after lung transplantation in 5/7 patients who had thrombocytopenia prior to the 
transplantation, reaching a platelets count of 25 G/L [8-28]. The 4 other patients did not present 
with thrombocytopenia, including 1 patient previously treated with azathioprine (Figure 1). Two 
patients who received azathioprine and one who received induction therapy with basiliximab, 
had worsening of thrombocytopenia (Figure 1). Two of the 3 patients treated with cyclosporine 
also had thrombocytopenia. Three patients received everolimus for a short duration without 
worsening of cytopenia. The thiopurine methyltransferase activity, which when low is 
associated with azathioprine toxicity [14], was available for 2 patients with severe pancytopenia 
and was normal.  
All the patients developed anemia (Figure 1). Three patients had neutropenia with neutrophils 
counts of 0.1, 0.8 and 0.8 G/L, respectively. Two of them also had a thrombotic microangiopathy 
at that time. Bone marrow cytology was consistent with a myelodysplastic syndrome in 6 
patients (Table 4): refractory anemia with excess blasts type 1 (n=1), refractory cytopenia with 
multilineage dysplasia (n=4), refractory cytopenia with unilineage dysplasia (n=1).  
Severe infections occurred in 6 patients (Table 4). One patient had pulmonary infection with 
Pneumocystis jiroveci while co-trimoxazole was withdrawn due to cytopenia. Isolated CMV 
viremia developed in 3 patients, whose treatment by ganciclovir was limited by cytopenia.  
Except thrombotic microangiopathy, which occurred in 2 cases, no patient presented acute 
renal failure. These patients died while they were still in need for dialysis. Only 1 patient had 
mildly elevated liver enzymes (below twice the upper limit of normal). 
DISCUSSION 
This is the largest report on outcomes of lung transplantation in a comprehensive series of 
patients with TERT or TR mutations. The main finding of the present study is that hematological 
complications following lung transplantation were more frequent in this patient population than 
in a control group of lung transplant recepients for PF, with possible sepsis related to bone 
marrow failure, therefore warranting close attention of clinicians both for the pre-transplant 
evaluation, and in the post-transplant follow-up period.  
Patients with familial PF are usually younger than 65 years, and may therefore be considered as 
adequate candidates for lung transplantation [8, 15]. Our series underscores that TERT and TR 
mutations may be revealed not only by familial history of PF but also by extra-pulmonary signs 
of telomere syndrome such as bone marrow failure or liver disease [16]. Moreover 
hematological complications, mainly thrombocytopenia, may be absent at the time of diagnosis 
and develop during follow-up particularly in subjects receiving cytotoxic drugs.  
Our data indicate that cytopenia, and particularly thrombocytopenia, is a common complication 
in telomerase mutation carriers exposed to cytotoxic drugs. Compared to matched family 
members without mutation, patients with TERT mutations have lower platelets count although 
generally within normal limits [17]. The co-occurrence of bone marrow failure and PF in the 
same individual or family is highly predictive of telomerase mutation [18]. In a previous series 
[9], all patients with telomerase mutations and PF had thrombocytopenia after lung 
transplantation, with a majority of them requiring platelet transfusion. Nearly all our patients 
had anemia after lung transplantation, and neutropenia was frequent with cytotoxic drugs, 
however thrombocytopenia was the most prominent manifestation. Thrombocytopenia should 
be considered highly suggestive of telomerase mutations in this setting.  
The median survival of 214 days following transplantation in this series was very low, compared 
to that reported by the International Society for Heart and Lung Transplantation (ISHLT) in 
transplant recipients with PF, who have a median survival of 4.3 years [19]. However, mortality 
could be increased due to the high rate (55%) of high emergency lung transplantation and to the 
frequent use of extracorporeal circulation [20]. The survival time in our series also compares 
unfavourably with the study of Silhan et al., in which 7 of their 8 patients were still alive after a 
median follow-up of 1.9 years [9]. However, the small number of patients in the latter series (e.g. 
only 8 patients identified among transplant recipients from the USA, Australia, and Sweden), 
may suggest that results by Silhan et al., be biased by selection and recall bias, with possible 
underdiagnosis of PF related to telomerase mutations and/or underestimation of the severity of 
complications (early deaths are frequently underrepresented in retrospective series [21]). The 
present series may better and more realistically reflect the severity of complications in 
transplant recipients carrying telomerase mutations. In addition, differences in 
immunosuppressive regimen between the present series and that of Silhan et al., may have 
contributed to differences in outcome. Indeed, while most subjects in the Silhan study received 
a two-drug immunosuppressive regimen, all the patients from our cohort received a third 
additional immunosuppressive drug. Of note, data from the literature further suggest that 
azathioprine may be more toxic than mycophenolate mofetil in this setting [22], an hypothesis 
that needs to be evaluated. Azathioprine, mycophenolate mofetil and cyclophosphamide likely 
contributed to the haematological complications. In our study, all patients received drugs with 
established hematological toxicity co-trimoxazole (N=9), ganciclovir (N=4), or voriconazole (N=4) 
but none received linezolid.  
In view of the poor results of transplantation, some patients from the current series might be 
considered contra-indicated for lung transplantation, especially those with myelodysplastic 
syndrome. In the future, genetic testing might be considered in the pre lung transplantation 
work-up.  
Two patients presented thrombotic microangiopathy, with low serum level of disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS13), and died. One patient from the 
current series presented low level of ADAMTS13 (<40% of the normal value) without thrombotic 
microangiopathy. Thrombotic microangiopathy has been previously reported after lung 
transplantation [23], and we speculate that ADAMTS13 synthesis might be reduced in patients 
with mutations even in the absence of cirrhosis.  
Identifying telomerase mutation may be challenging in patients evaluated for lung 
transplantation since myelodysplastic syndromes may only appear after cytotoxic drugs 
exposure, and the clinical / biological presentation may vary. The high rate of cytopenia after 
exposure to cytotoxic drugs in mutation carriers illustrates the abnormal repair capacities after 
external injury in these patients, and the phenotype heterogeneity according to age and 
environmental exposure. This is consistent with the fact that mutation carriers are more prone 
to develop liver cirrhosis associated to hepatitis C virus infection or alcohol exposure [24]. 
Similarly, environmental risk factors including tobacco or inhaled contaminants are found with a 
high frequency (96%) in patients with PF and a TERT mutation [8]. Indeed some patients with 
TERT or TERC mutations, without specific trigger could remain asymptomatic [8]. However TERT 
or TR mutations in the general population are very rare (<1/10000). 
All patients from this cohort fulfilled clinical telomere syndrome criteria. However some 
mutations have not been reported previously [9][25]. Three mutations were already published 
in the telomerase database and considered deleterious [26]. None of the novel mutations were 
found in database of controls (Exome variant server; 1000 Genome project), and Polyphen 
(polymorphism phenotyping) predicted all of them to be probably damaging. Telomere lengths 
assessed in 5 patients were shorter than that of age-matched controls in every case [13].  
Experience of organ transplantation in telomerase mutations carriers is very limited. In addition 
to series of lung transplantation (the series by Silhan et al. [9][25], and the present one), one 
report of liver transplantation has been published in a 63 year-old man with hepatocellular 
carcinoma, PF and TERT mutation, who experienced worsening of PF and died four months after 
the liver transplantation [27]. A patient with dyskeratosis congenita associated with a Telomeric 
Repeat-binding factor TRF1-Interacting Nuclear Factor 2 (TINF2) mutation, an additional 
mutation associated with the telomere syndrome [28], underwent lung transplantation for PF at 
the age of 13, ten years after receiving hematopoietic stem cell transplantation for severe 
aplastic anemia; he experienced neutropenia due to mycophenolate mofetil, which was 
withdrawn, and was reported to be doing well 21 months after lung transplantation with 
tacrolimus treatment. 
From a hematological point of view, patients with telomerase dysfunction are at high risk of 
pulmonary complications after hematopoietic stem cell transplantation [29]. Therefore a 
procedure with reduced immunosuppression is currently proposed for patients with 
dyskeratosis congenita [29-31]. Some reports suggest that mycophenolate mofetil and 
azathioprine may be safely removed from the drug regimen following lung transplantation [28, 
32]. Whether mycophenolate mofetil might be better tolerated than azathioprine in this setting 
warrants further study. 
One limitation of the present study is its retrospective design. However, the use of different 
sources (the single genetic laboratory with expertise in telomerase genes in France; all 
transplantation centers in France; and over 200 physicians participating to a network of clinical 
research on rare pulmonary diseases) ensured exhaustive identification in France of all cases of 
PF diagnosed with a mutation within the telomerase complex. It is conceivable that some cases 
with telomerase mutations may have been missed in the control group, as it can be 
hypothesized in the 2 patients with a diagnosis of myelodysplastic syndrome. Indeed, the TERT 
and TERC mutational status could not be analysed retrospectively in the control group. However 
TERT mutations were previously found in no more than 1-3% of sporadic IPF cases [34-35]. The 
diagnosis of myelodysplastic syndrome in the control group was retrieved by querying 
physicians, possibly underestimating its frequency. A prospective study with mutational status 
known before lung transplantation would be the only way to obtain definitive conclusions. 
Exhaustive collection of hematological data and of infectious events was comprehensively and 
reliably obtained through electronic patients charts. We therefore consider that this series is 
representative of the reality of lung transplantation in this particular population of patients.  
In conclusion, severe hematological complications are observed in patients with PF and 
mutations of the telomerase complex who receive a lung transplantation. We suggest thatlung 
transplantation should be discouraged in patients with myelodysplasia, and should be 
considered on a case-by-case basis in remaining cases. Specific recommendations should be 
developed for appropriate guidance regarding the hematological risk assessment before 
transplantation and the management of post-transplantation immunosuppressive regimen. 
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Table 1 Characteristics at the time of pulmonary fibrosis diagnosis  
Characteristics 
Patients 
N=9 
Male (%) 7 (77) 
Age at diagnosis, years  50 [35-61] 
Smoker ever/active 6 (66)/0(0) 
Occupational or environmental exposure* 6 (66) 
Extra-pulmonary symptoms of 
telomeropathy 
6 (66) 
 Hematological  
5 (55) 
- Platelets count <150G/L 4 (44) 
- Anemia 1 (11) 
- Macrocytosis 2 (22) 
 Cutaneous  3 (33) 
 Elevated liver enzymes  
1 (11) 
 
Data are presented as median [range] or n (%). Anemia was defined by WHO criteria. Macrocytosis was defined by 
a mean corpuscular volume (MCV) >100fL. 
* Two patients worked as farmers, two worked as construction workers, one as carpenter and one as polisher 
 
Table 2 Pre and post transplantation therapy and duration of treatment 
Drugs Pre-transplantation 
 
Post-transplantation 
 
Corticosteroids 
 
9 (100)/ 
625 days [128-2017] 
9 (100)/ 
214 days [59-1709] 
Azathioprine 
 
3 (33)/ 
792 days [118-1219] 
2 (22)/ 
80-219 days 
N-Acetylcysteine 
 
2 (22)/ 
594-625 days 
0 (0) 
Pirfenidone 
 
2 (22)/  
59-790 days 
0 (0) 
Cyclophophamide 
 
2 (22)/  
106-224 days 
0 (0) 
Proton Pump Inhibitor 
 
4 (44)/ 
na 
7 (77)/ 
na 
Mycophenolate mofetil 
 
0 (0) 9 (100)/ 
79 days [13-905] 
Tacrolimus 
 
0 (0) 9 (100)/ 
111 days [41-967] 
Cyclosporin 
 
0 (0) 3 (33)/ 
111 days [13-112] 
Everolimus 
 
0 (0) 3 (33)/ 
25 days [14-43] 
Basiliximab (induction) 
 
0 (0) 1 (11)/ 
4 days 
 
Data are presented as n (%). 
Duration of treatment is expressed as median [range] or minimum-maximum for n<3. na, not available. 
 
 
 
 Table 3 Mutations in hTERT, hTR and telomere lengths in the 9 probands 
Proband 
No. 
Age at 
presentation 
(years)  
Gender Gene Mutation Previously 
described 
mutation 
Telomere 
lengths 
(kb) 
 
1 38 M hTERT c.2911C>T, 
p.Arg971Cys 
No ND 
2 39 M hTERT c.2639C>T, 
p.Ala880Val 
No 5.26 
3 57 M hTERT c.1864C>T, 
p.Arg622Cys 
 
No ND 
4 61 M hTERT c.1630T>C, 
p.Phe544Leu 
No 4.32 
5 35 F hTERT c.2935C>T, 
p.Arg971Cys 
[1] 5.29 
6 58 M hTERT c.1710G>C, 
p.Lys570Asn 
[2] ND 
7 38 F hTR r.110_113delGACT 
 
[3-4] 4.3 
8 49 M hTR r.1-22C>T  No 3.3 
9 55 M hTR n.135G>C  
 
No ND 
Telomeres length was assessed by Southern blot and express in kb. Telomere lengths were always considered as 
telomere shortening
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Table 4 Pre-transplantation bone marrow cytology and evolution after lung transplantation 
 
Proband 
No. 
Age at 
transplantation, 
years 
Pulmonary 
diagnosis 
ECMO/High 
emergency 
procedure 
Pre-
transplantation 
bone marrow 
cytology, 
karyotype 
Post-
transplantation 
bone marrow 
cytology, 
karyotype 
Post-transplantation 
immunosuppression 
Post-
transplantation 
infections (no.) 
Status Follow
-up 
(days) 
Cause of 
Death 
1 42 HP  Yes/no Unilineage 
megakaryocytic 
dysplasia, normal 
Multilineage 
dysplasia, 7% 
blasts, normal 
Cs Aza MMF FK Pneumocystosis Alive 310 NA 
2 40 IPF Yes/yes ND Multilineage 
dysplasia, i(7q), 
i(3q) 
Cs MMF Cyc FK Bacterial 
Pneumonia (3) 
Candida sepsis (1) 
Bacterial sepsis 
(3) 
Dead 197 Pancytop
enia 
3 59 IPF Yes/yes  ND  Multilineage 
dysplasia, normal 
Cs MMF Cyc FK Bacterial 
Pneumonia (3) 
Bacterial sepsis 
(1) 
Dead 59 Sepsis  
4 62 Pneumoconiosis Yes/yes Unilineage 
megakaryocytic 
dysplasia, normal 
ND Cs MMF FK Bacterial 
Pneumonia (2) 
Pyothorax (1) 
Dead 79 Pulmonar
y 
embolis
m 
5  39 IPF No/no ND ND Cs MMF FK Tuberculosis Alive 1709 NA 
 
6  58 IPF No/no Normal, ND Multilineage 
dysplasia, normal 
Cs Aza MMF FK Eve CMV reactivation 
Bacterial 
pneumonia (2) 
Bacterial sepsis 
(1) 
Dead 214 Sepsis  
7  45 IPF No/no Unilineage 
megakaryocytic 
dysplasia, normal 
Multilineage 
dysplasia, ND 
Cs MMF FK Eve Basi CMV reactivation 
HHV6 encephalitis 
Bacterial 
Pneumonia (1) 
Bacterial sepsis 
(1) 
Dead 84 Pancytop
enia 
8  52 IPF Yes/yes ND 
Unilineage 
megakaryocytic 
dysplasia, ND 
Cs MMF FK Bacterial 
Pneumonia (3) 
Bacterial sepsis 
(1) 
Alive 747 NA 
9 58 IPF No/yes ND ND Cs MMF Cyc FK Eve CMV reactivation Dead 650 Unknown 
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NA, not applicable; ND, not done,; HP, chronic hypersensitivity pneumonitis; IPF, idiopathic pulmonary fibrosis; ECMO, use of extracorporeal 
circulation; Cs, corticosteroids; Aza, azathioprine; MMF, mycophenolate mofetil; FK tacrolimus; Cyc, cyclosporine; Eve, everolimus; Basi, 
basiliximab 
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Figures 
 
Figure 1 Evolution of platelet, neutrophil and hemoglobin counts at pulmonary fibrosis diagnosis, before lung transplantation 
(pre-LT) and 3 months after lung transplantation (M3) or last available data before death and post lung transplantation (post-
LT) nadir by post-transplantation therapy. The horizontal dashed lines highlight the normal values. Because of the frequent 
use of extracorporeal circulation, nadir of thrombocytopenia was defined starting at day 7 post-transplantation. Dashed lines: 
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patients who received azathioprine or induction therapy (          ), patients who received cyclosporine (          ). Continuous 
lines: patients who did not receive azathioprine, induction therapy nor cyclosporine (         ). 
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Figure 2 Kaplan-Meier estimation of overall survival after lung transplantation for 9 telomerase mutation carriers. 
 
 
 
 
